143 related articles for article (PubMed ID: 31778714)
1. High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti-TNF-α Therapy.
Sanz-Martínez MT; Moga E; Sánchez Martínez MA; Zamora Atenza C; Vidal S; Juárez C; Puig L
J Invest Dermatol; 2020 Jun; 140(6):1176-1183. PubMed ID: 31778714
[TBL] [Abstract][Full Text] [Related]
2. TNF-α inhibitors reduce the pathological Th
Campanati A; Orciani M; Lazzarini R; Ganzetti G; Consales V; Sorgentoni G; Di Primio R; Offidani A
Exp Dermatol; 2017 Apr; 26(4):319-324. PubMed ID: 27376466
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis.
Luan L; Han S; Wang H; Liu X
Int Immunopharmacol; 2015 Dec; 29(2):278-284. PubMed ID: 26585971
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
[TBL] [Abstract][Full Text] [Related]
5. T-helper immune phenotype may underlie 'paradoxical' tumour necrosis factor-α inhibitor therapy-related psoriasiform dermatitis.
Moy AP; Murali M; Kroshinsky D; Horn TD; Nazarian RM
Clin Exp Dermatol; 2018 Jan; 43(1):19-26. PubMed ID: 28940220
[TBL] [Abstract][Full Text] [Related]
6. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.
Ortega C; Fernández-A S; Carrillo JM; Romero P; Molina IJ; Moreno JC; Santamaría M
J Leukoc Biol; 2009 Aug; 86(2):435-43. PubMed ID: 19487306
[TBL] [Abstract][Full Text] [Related]
7. Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α.
Langkilde A; Olsen LC; Sætrom P; Drabløs F; Besenbacher S; Raaby L; Johansen C; Iversen L
PLoS One; 2016; 11(12):e0167437. PubMed ID: 28005985
[TBL] [Abstract][Full Text] [Related]
8. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
9. TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expression.
Urbano PCM; Aguirre-Gamboa R; Ashikov A; van Heeswijk B; Krippner-Heidenreich A; Tijssen H; Li Y; Azevedo VF; Smits LJT; Hoentjen F; Joosten I; Koenen HJPM
J Allergy Clin Immunol; 2018 Aug; 142(2):517-529. PubMed ID: 29248493
[TBL] [Abstract][Full Text] [Related]
10. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation.
Lin SH; Chuang HY; Ho JC; Lee CH; Hsiao CC
J Dermatol Sci; 2018 Sep; 91(3):276-284. PubMed ID: 29914850
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti-TNF-α treatment.
Balato A; Lembo S; Ayala F; Balato N; Caiazzo G; Raimondo A; Di Caprio R; Monfrecola G
Exp Dermatol; 2017 Apr; 26(4):325-327. PubMed ID: 27943462
[No Abstract] [Full Text] [Related]
12. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
Engin B; Tanakol A; Bulut H; Songür A; Vehid HE; Gökalp E; Kutlubay Z; Özkoca D; Tüzün Y; Serdaroğlu S
Int J Dermatol; 2020 Feb; 59(2):207-215. PubMed ID: 31531981
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study.
Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Corrales A; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Llorca J; Gonzalez-Gay MA
J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):92-5. PubMed ID: 25650695
[TBL] [Abstract][Full Text] [Related]
14. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics.
Stoffel E; Maier H; Riedl E; Brüggen MC; Reininger B; Schaschinger M; Bangert C; Guenova E; Stingl G; Brunner PM
Br J Dermatol; 2018 May; 178(5):1151-1162. PubMed ID: 29143979
[TBL] [Abstract][Full Text] [Related]
15. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684
[TBL] [Abstract][Full Text] [Related]
16. Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis.
Andersen CSB; Kvist-Hansen A; Siewertsen M; Enevold C; Hansen PR; Kaur-Knudsen D; Zachariae C; Nielsen CH; Loft N; Skov L
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047086
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-α therapy.
Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Corrales A; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
J Dermatol; 2016 Apr; 43(4):389-94. PubMed ID: 26364678
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis.
Campanati A; Ganzetti G; Giuliodori K; Marra M; Bonfigli A; Testa R; Offidani A
Int J Dermatol; 2015 Jul; 54(7):839-45. PubMed ID: 25877149
[TBL] [Abstract][Full Text] [Related]
19. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study.
Gkalpakiotis S; Arenbergerova M; Gkalpakioti P; Potockova J; Arenberger P; Kraml P
J Dermatol; 2017 Apr; 44(4):363-369. PubMed ID: 27774694
[TBL] [Abstract][Full Text] [Related]
20. Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease.
Navarrete-Dechent C; Majerson D; Torres M; Armijo D; Patel M; Menter A; de la Cruz C
An Bras Dermatol; 2015; 90(3 Suppl 1):171-4. PubMed ID: 26312707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
